Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Liabilities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Liabilities for 4 consecutive years, with $66.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 16.71% to $66.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.7 million through Dec 2025, down 16.71% year-over-year, with the annual reading at $66.7 million for FY2025, 16.71% down from the prior year.
  • Total Liabilities for Q4 2025 was $66.7 million at Day One Biopharmaceuticals, up from $62.9 million in the prior quarter.
  • The five-year high for Total Liabilities was $93.7 million in Q2 2024, with the low at $8.2 million in Q1 2022.
  • Average Total Liabilities over 4 years is $40.7 million, with a median of $29.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities surged 279.35% in 2024, then tumbled 37.89% in 2025.
  • Over 4 years, Total Liabilities stood at $17.0 million in 2022, then soared by 73.34% to $29.5 million in 2023, then soared by 171.24% to $80.0 million in 2024, then fell by 16.71% to $66.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $66.7 million, $62.9 million, and $58.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.